Published online Oct 19, 2025. doi: 10.5498/wjp.v15.i10.109425
Revised: June 27, 2025
Accepted: August 8, 2025
Published online: October 19, 2025
Processing time: 139 Days and 1.2 Hours
Major depressive disorder (MDD) is a significant psychiatric condition that poses a serious threat to human life, primarily due to its association with suicidal beha
To reveal the biological and pathological significance of B4GALT6 in the brain and MDD.
An inflammation-associated depression mouse model was developed by treating mice with lipopolysaccharides. B4GALT6-like immunoreactivity distribution and expression level was examined throughout the brain.
B4GALT6-like immunoreactivity increased in the hippocampus, PrL, and the vi
Although the neuropathological role of B4GALT6 in the brain remains to be fully characterized, B4GALT6 may be a potential therapeutic target for MDD.
Core Tip: Major depressive disorder (MDD) poses a serious threat to human life. The single nucleotide polymorphism rs372369000 located within the B4GALT6 gene is a risk locus for MDD. However, the pathological mechanism of B4GALT6 in the brain in relation to MDD remains unclear. We developed an inflammation-associated depression model and examined B4GALT6-like immunoreactivity distribution and levels throughout the brain. The expression of B4GALT6-like immunoreactivity increased in the hippocampus, PrL, and the visual cortex V1 region of MDD mice. This elevation varied across different brain subregions and cell types. Taken together, our data suggest that B4GALT6 may be a potential therapeutic target for MDD.